- Email: [email protected]
Anxiety levels increase chronic musculoskeletal pain in Alzheimer's disease patients
e336
Abstracts / Journal of the Neurological Sciences 333 (2013) e292–e357
Objective: To clarify the role of the BDNF in SCZ, protein levels and polymorphism in SCZ-affected and healthy subjects were evaluated. Patients and methods: In this study, the BDNF blood levels in chronic patients with paranoid SCZ treated with antipsychotics, antipsychotic-naïve patients, and controls were evaluated by ELISA. Results: Comparative analysis showed 1.45-fold decreased BDNF levels in SCZ when compared to controls (p = 2.27E−23). Also, there was a significant difference in levels of BDNF between antipsychoticnaïve patients and controls (p = 8.2E−07), whereas treated patients were not differed from antipsychotic-naïve (p N 0.05). With regard to gender, reduced BDNF levels in females compared to males both in patients (p = 0.0018) and controls (p = 0.019) were found. We compared the BDNF levels with regard to the Val66Met genotypes in SCZ patients and controls based upon our previous data. Relevant intragroup analysis showed increased BDNF levels in 66Met allele carriers when compared to Val/Val both in SCZ (p = 0.0003) and controls (p = 4.22E−05). Conclusion: To summarize, the results obtained suggest that decreased BDNF levels associate with 66Met allele carriers and might be involved in the pathogenesis of SCZ in Armenian population. All authors declare that they read and are aware of the content of abstract. doi:10.1016/j.jns.2013.07.1242
Abstract — WCN 2013 No: 1928 Topic: 5 — Dementia Predictors of response to the 13.3 and 9.5 mg/24 h rivastigmine patch: The optimizing transdermal exelon in mild-to-moderate Alzheimer's disease (optima) study J.L. Molinuevoa, G. Grossbergb, L. Frölichc, J. Galvind, T. Krahnkee, C. Strohmaiere. aAlzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, ICN Hospital Clinic i Universitari, Barcelona, Spain; b Department of Neurology and Psychiatry, St. Louis University School of Medicine, St. Louis, MO, USA; cDepartment of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; dCenter of Excellence on Brain Aging, New York University Langone Medical Center, New York, NY, USA; e Novartis Pharma AG, Basel, Switzerland Background: The OPTIMA study (NCT00506415) demonstrated reduced deterioration with 13.3 versus 9.5 mg/24 h rivastigmine patch in patients with Alzheimer's disease (AD). Treatment response can vary according to patients' individual characteristics. We conducted a responder analysis to identify the proportion of patients demonstrating a treatment response to each dose, and patient characteristics predictive of achieving a response. Methods: Details of OPTIMA are published (Cummings et al., 2012). Patients meeting pre-specified decline criteria during treatment with 9.5 mg/24 h patch, entered a 48-week, double-blind (DB) phase, and were randomized to 13.3 or 9.5 mg/24 h. ADAS-cog and ADCS-IADL were co-primary endpoints. In this post-hoc analysis, the following criteria for achieving a treatment response at weeks 24 and 48 were applied: ≥4 points' improvement on ADAS-cog, and ≥4 points' improvement on ADAS-cog combined with no decline on ADCS-IADL. Results: Demographics and baseline scores were comparable between patient groups (13.3 mg/24 h, N = 265; 9.5 mg/24 h, N = 271). At week 24, 25 versus 14% (p = 0.001) of patients receiving 13.3 and 9.5 mg/24 h patch, respectively, demonstrated ≥4 points' improvement on ADAS-cog, and 17 versus 7% (p b 0.001) demonstrated ≥4 points' improvement on ADAS-cog and no decline on ADCS-IADL. Of patients receiving 13.3 and 9.5 mg/24 h patch, respectively, at Week 48, 16% and 10% (p = 0.020) displayed ≥4 points' improvement on
ADAS-cog, and 8% versus 4% (p = 0.023) demonstrated ≥4 points' improvement on ADAS-cog and no decline on ADCS-IADL. Conclusion: Titration of patients with mild-to-moderate AD to the high-dose (13.3 mg/24 h) rivastigmine patch (15 cm2) increases the likelihood of achieving a clinically-meaningful treatment response. doi:10.1016/j.jns.2013.07.1243
Abstract WCN 2013 No: 1906 Topic: 5 — Dementia Efficacy and safety of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease with and without concomitant memantine use G. Grossberga, M. Farlowb, X. Mengc, M. Somogyic. aDepartment of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO, USA; bDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA; cNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA Background: The ACTivities of daily living and cognitION (ACTION) study demonstrated significant efficacy of 13.3 versus 4.6 mg/24 h rivastigmine patch on SIB and ADCS-ADL-SIV in severe Alzheimer's disease (AD). 61% of the study population was on concomitant memantine (regardless of dose or duration). Here the effect of concomitant memantine use on efficacy and safety of 13.3 mg/24 h patch was investigated. Methods: ACTION was a 24-week, randomized, double-blind study in patients with severe AD (MMSE score 3–12).Patients randomized to 13.3 or 4.6 mg/24 h patch were subdivided according to whether they received ≥1 dose of concomitant memantine. Change from baseline at week 24 on SIB and ADCS-ADL-SIV was assessed. Safety evaluations included incidence of adverse events (AEs). Results: Overall, memantine-treated patients, had a lower MMSE at screening (8.6 +/− 2.91 versus 9.2 +/− 2.88). At week 24, the 13.3 demonstrated significantly greater efficacy than 4.6 mg/24 h patch on SIB and ADCS-ADL-SIV in patients receiving concomitant memantine than in those not receiving memantine (p b 0.05 for all). The incidence of AEs was 71.4% with 13.3 mg/24 h patch and memantine, 79.7% with 13.3 mg/24 h patch without memantine, 74.7% with 4.6 mg/24 h patch with memantine, and 71.1% with 4.6 mg/24 h patch without memantine. Conclusions: These data suggest benefit of 13.3 mg/24 h patch, regardless of concomitant memantine use, and demonstrate similar safety and tolerability of 13.3 mg/24 h patch in memantine-treated patients and those not receiving memantine. doi:10.1016/j.jns.2013.07.1244
Abstract — WCN 2013 No: 2308 Topic: 5 — Dementia Anxiety levels increase chronic musculoskeletal pain in Alzheimer's disease patients V. Papaliagkasa, M. Tsatalib, D. Damigosb, V. Mavreasc, M. Gouvad, M. Tsolakia. aThird Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; bMedical Psychology, Greece; c University of Ioannina-School of Medicine, Greece; dNursing, Higher Technological Educational Institute of Epirus, Ioánnina, Greece Background: Mood disorders in Alzheimer's Disease (AD) patients result in great difficulties in clinical practice in the assessment of pain and further treatment, therefore they should be early diagnosed and managed.
Abstracts / Journal of the Neurological Sciences 333 (2013) e292–e357
Material and methods: Twenty five AD patients, with anxiety and chronic musculoskeletal pain (experimental group) and thirty one age-matched patients with Alzheimer's disease and chronic musculoskeletal pain without comorbid mood disorders (control group) were examined. All participants were diagnosed with chronic musculoskeletal pain, according to their medical history and their medications (all of them took non-steroid anti-inflammatory drugs). The neuropsychometric evaluations were performed with the following tools: Geriatric Pain Measure, Patient Health Questionnaire, Pain Assessment in Advanced Dementia, Mini Mental State Examination and Pain Anxiety Symptom Scale. Results: AD patients with comorbid anxiety disorders tend to report increased pain intensity more frequently compared to controls. Scores in fearful thinking and physiological responses scales of PASS were higher in female than male (p = .014), whereas scores in the cognitive anxiety scale of PASS have shown a highly significant positive correlation with the years of education (p b .001). Discussion: According to the results of the present study, anxiety is a significant component and an important part of pain experience among patients with AD, even if they are not able to verbalize it; thus needs to be taken into consideration by the health professionals for the patient's management.
doi:10.1016/j.jns.2013.07.1245
Abstract — WCN 2013 No: 2390 Topic: 5 — Dementia Catechin supressed LPS-induced neuroinflammation in BV-2, C6 and NG108-15 cells by modulating CCL21 through PI3K-Akt M.N.A. Kamarudin, H. Abdul Kadir, N.A. Mohd Raflee. Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia Background and objectives: Excessive microglial and astroglial activation that leads to chronic neuroinflammation plays a vital role in the progression of Alzheimer's, Parkinson's and Huntington's diseases. Catechin or flavan-3-ol is mainly found in tea is reported to be neuroprotective. We investigated the regulation of neuroinflammation of LPS-induced neuroinflammation in BV-2, C6 and SHSY-5Y cells. Material and methods: The expression of NO, ROS, PGE2, TNF-α, IL1β, IL-2, IL-6, IFN-γ, iNOS, COX-2, CCL21 and the molecular pathways involved were determined by Flow cytometry chip beads array (CBA), Western blot and ICC. The protective effects of catechin on BV-2 and SH-SY5Y co-cultured model induced with LPS were further evaluated. Results: Catechin downregulated iNOS expression leading to concomitant decreased of NO and ROS released. This was followed by reduction of PGE2 production leading to downregulation of TNF-α, IL-1β, IL-2, IL-6, IFN-γ and COX-2 expression. Catechin downregulated CCL21 and prevented Iκβα degradation and thus, prevented p65 NF-κβ translocation in BV-2 and SH-SY5Y cells. Withal, Catechin upregulated PI3K-Akt expression, suggesting activation of pAkt might be responsible in mitigation of neuroinflammation. Conclusion: Suppresion of CCL21 in BV-2 and C6 activation through PI3K-Akt by catechin conferred protection on SH-SY5Y cells against LPS-induced neuroinflammation. This finding further heightens the specific therapeutic potential of cathechin for the treatment of neurodegenerative diseases.
doi:10.1016/j.jns.2013.07.1246
e337
Abstract — WCN 2013 No: 2400 Topic: 5 — Dementia The impact of neurological condition on driver distraction in a driving simulator experiment: Preliminary findings A. Economoua, I. Beratisb, M.H. Kosmidisc, A. Liosidoub, N. Andronasb, J. Papatriantafylloud, G. Yiannise, S.G. Papageorgioub. aDepartment of Psychology, University of Athens, Greece; bDepartment of Neurology, 'Attikon' University General Hospital, University of Athens, Athens, Greece; cDepartment of Psychology, Aristotle University of Thessaloniki, Thessaloníki, Greece; dIASIS Community Medical Center for the Elderly, Greece; eDepartment of Transportation Planning and Engineering, National Technical University of Athens, Athens, Greece Background: Age-related neurological disorders may affect driver distraction, and medication may also impair driving. In the early stages, neurological disorders have little impact on daily life yet may significantly impact one's driving ability. Mild cognitive impairment (MCI), the predementia stage of various dementing disorders, is associated with impaired driving to a small extent (Frittelli et al., 2009) and self-reported road accident involvement is correlated with future diagnosis of dementia (Lafont et al., 2008). It is unknown whether distraction affects the driving ability of neurology patients to the same extent as healthy persons. Because of the ageing population, the need to investigate this question becomes critical. Objective: To present preliminary findings from a recently funded research programme, National Strategic Reference Framework (NSRF 2007-13, O.P. Thales), on the causes and impact of driver distraction in a driving simulator experiment. Patients and methods: At least 90 patients with neurological disorders (MCI, mild Alzheimer's disease, Parkinson's disease) will be recruited, and will be compared with at least 60 middle aged and older participants. A neuropsychological battery that measures attention, memory, visual and executive functions, a neurological exam, and a detailed history of medication and sleep difficulties are included. Results: Preliminary findings are presented on the impact of presence/severity of neurological disorder, use of medications, and sleep disorders on driving performance with and without distraction, under different driving conditions. Conclusion: The neurological parameters that predict driving performance under different conditions are summarized and discussed. Preliminary recommendations are presented on criteria for safe driving.
doi:10.1016/j.jns.2013.07.1247
Abstract — WCN 2013 No: 2313 Topic: 5 — Dementia Potential effect of amyloid imaging on diagnosis and intended management of patients with cognitive decline: Impact of appropriate use criterion M.J. Pontecorvoa, A. Siderowfa, G. Dell'Agnellob, M. Lua, C. Hunterc, A.K. Aroraa, M.A. Mintuna. aAvid Radiopharmaceuticals, Philadelphia, PA, USA; bEli Lilly and Company, Florence, Italy; cEli Lilly and Company, Indianapolis, IN, USA Background: Published appropriate use criteria (AUC) by Johnson et al. (2013), provide guidelines for selecting patients for whom amyloid PET could be useful. Objectives: To evaluate the impact of amyloid PET on diagnosis and intended management in a set of patients likely to meet AUC.
Abstracts / Journal of the Neurological Sciences 333 (2013) e292–e357
Objective: To clarify the role of the BDNF in SCZ, protein levels and polymorphism in SCZ-affected and healthy subjects were evaluated. Patients and methods: In this study, the BDNF blood levels in chronic patients with paranoid SCZ treated with antipsychotics, antipsychotic-naïve patients, and controls were evaluated by ELISA. Results: Comparative analysis showed 1.45-fold decreased BDNF levels in SCZ when compared to controls (p = 2.27E−23). Also, there was a significant difference in levels of BDNF between antipsychoticnaïve patients and controls (p = 8.2E−07), whereas treated patients were not differed from antipsychotic-naïve (p N 0.05). With regard to gender, reduced BDNF levels in females compared to males both in patients (p = 0.0018) and controls (p = 0.019) were found. We compared the BDNF levels with regard to the Val66Met genotypes in SCZ patients and controls based upon our previous data. Relevant intragroup analysis showed increased BDNF levels in 66Met allele carriers when compared to Val/Val both in SCZ (p = 0.0003) and controls (p = 4.22E−05). Conclusion: To summarize, the results obtained suggest that decreased BDNF levels associate with 66Met allele carriers and might be involved in the pathogenesis of SCZ in Armenian population. All authors declare that they read and are aware of the content of abstract. doi:10.1016/j.jns.2013.07.1242
Abstract — WCN 2013 No: 1928 Topic: 5 — Dementia Predictors of response to the 13.3 and 9.5 mg/24 h rivastigmine patch: The optimizing transdermal exelon in mild-to-moderate Alzheimer's disease (optima) study J.L. Molinuevoa, G. Grossbergb, L. Frölichc, J. Galvind, T. Krahnkee, C. Strohmaiere. aAlzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, ICN Hospital Clinic i Universitari, Barcelona, Spain; b Department of Neurology and Psychiatry, St. Louis University School of Medicine, St. Louis, MO, USA; cDepartment of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; dCenter of Excellence on Brain Aging, New York University Langone Medical Center, New York, NY, USA; e Novartis Pharma AG, Basel, Switzerland Background: The OPTIMA study (NCT00506415) demonstrated reduced deterioration with 13.3 versus 9.5 mg/24 h rivastigmine patch in patients with Alzheimer's disease (AD). Treatment response can vary according to patients' individual characteristics. We conducted a responder analysis to identify the proportion of patients demonstrating a treatment response to each dose, and patient characteristics predictive of achieving a response. Methods: Details of OPTIMA are published (Cummings et al., 2012). Patients meeting pre-specified decline criteria during treatment with 9.5 mg/24 h patch, entered a 48-week, double-blind (DB) phase, and were randomized to 13.3 or 9.5 mg/24 h. ADAS-cog and ADCS-IADL were co-primary endpoints. In this post-hoc analysis, the following criteria for achieving a treatment response at weeks 24 and 48 were applied: ≥4 points' improvement on ADAS-cog, and ≥4 points' improvement on ADAS-cog combined with no decline on ADCS-IADL. Results: Demographics and baseline scores were comparable between patient groups (13.3 mg/24 h, N = 265; 9.5 mg/24 h, N = 271). At week 24, 25 versus 14% (p = 0.001) of patients receiving 13.3 and 9.5 mg/24 h patch, respectively, demonstrated ≥4 points' improvement on ADAS-cog, and 17 versus 7% (p b 0.001) demonstrated ≥4 points' improvement on ADAS-cog and no decline on ADCS-IADL. Of patients receiving 13.3 and 9.5 mg/24 h patch, respectively, at Week 48, 16% and 10% (p = 0.020) displayed ≥4 points' improvement on
ADAS-cog, and 8% versus 4% (p = 0.023) demonstrated ≥4 points' improvement on ADAS-cog and no decline on ADCS-IADL. Conclusion: Titration of patients with mild-to-moderate AD to the high-dose (13.3 mg/24 h) rivastigmine patch (15 cm2) increases the likelihood of achieving a clinically-meaningful treatment response. doi:10.1016/j.jns.2013.07.1243
Abstract WCN 2013 No: 1906 Topic: 5 — Dementia Efficacy and safety of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease with and without concomitant memantine use G. Grossberga, M. Farlowb, X. Mengc, M. Somogyic. aDepartment of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO, USA; bDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA; cNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA Background: The ACTivities of daily living and cognitION (ACTION) study demonstrated significant efficacy of 13.3 versus 4.6 mg/24 h rivastigmine patch on SIB and ADCS-ADL-SIV in severe Alzheimer's disease (AD). 61% of the study population was on concomitant memantine (regardless of dose or duration). Here the effect of concomitant memantine use on efficacy and safety of 13.3 mg/24 h patch was investigated. Methods: ACTION was a 24-week, randomized, double-blind study in patients with severe AD (MMSE score 3–12).Patients randomized to 13.3 or 4.6 mg/24 h patch were subdivided according to whether they received ≥1 dose of concomitant memantine. Change from baseline at week 24 on SIB and ADCS-ADL-SIV was assessed. Safety evaluations included incidence of adverse events (AEs). Results: Overall, memantine-treated patients, had a lower MMSE at screening (8.6 +/− 2.91 versus 9.2 +/− 2.88). At week 24, the 13.3 demonstrated significantly greater efficacy than 4.6 mg/24 h patch on SIB and ADCS-ADL-SIV in patients receiving concomitant memantine than in those not receiving memantine (p b 0.05 for all). The incidence of AEs was 71.4% with 13.3 mg/24 h patch and memantine, 79.7% with 13.3 mg/24 h patch without memantine, 74.7% with 4.6 mg/24 h patch with memantine, and 71.1% with 4.6 mg/24 h patch without memantine. Conclusions: These data suggest benefit of 13.3 mg/24 h patch, regardless of concomitant memantine use, and demonstrate similar safety and tolerability of 13.3 mg/24 h patch in memantine-treated patients and those not receiving memantine. doi:10.1016/j.jns.2013.07.1244
Abstract — WCN 2013 No: 2308 Topic: 5 — Dementia Anxiety levels increase chronic musculoskeletal pain in Alzheimer's disease patients V. Papaliagkasa, M. Tsatalib, D. Damigosb, V. Mavreasc, M. Gouvad, M. Tsolakia. aThird Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; bMedical Psychology, Greece; c University of Ioannina-School of Medicine, Greece; dNursing, Higher Technological Educational Institute of Epirus, Ioánnina, Greece Background: Mood disorders in Alzheimer's Disease (AD) patients result in great difficulties in clinical practice in the assessment of pain and further treatment, therefore they should be early diagnosed and managed.
Abstracts / Journal of the Neurological Sciences 333 (2013) e292–e357
Material and methods: Twenty five AD patients, with anxiety and chronic musculoskeletal pain (experimental group) and thirty one age-matched patients with Alzheimer's disease and chronic musculoskeletal pain without comorbid mood disorders (control group) were examined. All participants were diagnosed with chronic musculoskeletal pain, according to their medical history and their medications (all of them took non-steroid anti-inflammatory drugs). The neuropsychometric evaluations were performed with the following tools: Geriatric Pain Measure, Patient Health Questionnaire, Pain Assessment in Advanced Dementia, Mini Mental State Examination and Pain Anxiety Symptom Scale. Results: AD patients with comorbid anxiety disorders tend to report increased pain intensity more frequently compared to controls. Scores in fearful thinking and physiological responses scales of PASS were higher in female than male (p = .014), whereas scores in the cognitive anxiety scale of PASS have shown a highly significant positive correlation with the years of education (p b .001). Discussion: According to the results of the present study, anxiety is a significant component and an important part of pain experience among patients with AD, even if they are not able to verbalize it; thus needs to be taken into consideration by the health professionals for the patient's management.
doi:10.1016/j.jns.2013.07.1245
Abstract — WCN 2013 No: 2390 Topic: 5 — Dementia Catechin supressed LPS-induced neuroinflammation in BV-2, C6 and NG108-15 cells by modulating CCL21 through PI3K-Akt M.N.A. Kamarudin, H. Abdul Kadir, N.A. Mohd Raflee. Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia Background and objectives: Excessive microglial and astroglial activation that leads to chronic neuroinflammation plays a vital role in the progression of Alzheimer's, Parkinson's and Huntington's diseases. Catechin or flavan-3-ol is mainly found in tea is reported to be neuroprotective. We investigated the regulation of neuroinflammation of LPS-induced neuroinflammation in BV-2, C6 and SHSY-5Y cells. Material and methods: The expression of NO, ROS, PGE2, TNF-α, IL1β, IL-2, IL-6, IFN-γ, iNOS, COX-2, CCL21 and the molecular pathways involved were determined by Flow cytometry chip beads array (CBA), Western blot and ICC. The protective effects of catechin on BV-2 and SH-SY5Y co-cultured model induced with LPS were further evaluated. Results: Catechin downregulated iNOS expression leading to concomitant decreased of NO and ROS released. This was followed by reduction of PGE2 production leading to downregulation of TNF-α, IL-1β, IL-2, IL-6, IFN-γ and COX-2 expression. Catechin downregulated CCL21 and prevented Iκβα degradation and thus, prevented p65 NF-κβ translocation in BV-2 and SH-SY5Y cells. Withal, Catechin upregulated PI3K-Akt expression, suggesting activation of pAkt might be responsible in mitigation of neuroinflammation. Conclusion: Suppresion of CCL21 in BV-2 and C6 activation through PI3K-Akt by catechin conferred protection on SH-SY5Y cells against LPS-induced neuroinflammation. This finding further heightens the specific therapeutic potential of cathechin for the treatment of neurodegenerative diseases.
doi:10.1016/j.jns.2013.07.1246
e337
Abstract — WCN 2013 No: 2400 Topic: 5 — Dementia The impact of neurological condition on driver distraction in a driving simulator experiment: Preliminary findings A. Economoua, I. Beratisb, M.H. Kosmidisc, A. Liosidoub, N. Andronasb, J. Papatriantafylloud, G. Yiannise, S.G. Papageorgioub. aDepartment of Psychology, University of Athens, Greece; bDepartment of Neurology, 'Attikon' University General Hospital, University of Athens, Athens, Greece; cDepartment of Psychology, Aristotle University of Thessaloniki, Thessaloníki, Greece; dIASIS Community Medical Center for the Elderly, Greece; eDepartment of Transportation Planning and Engineering, National Technical University of Athens, Athens, Greece Background: Age-related neurological disorders may affect driver distraction, and medication may also impair driving. In the early stages, neurological disorders have little impact on daily life yet may significantly impact one's driving ability. Mild cognitive impairment (MCI), the predementia stage of various dementing disorders, is associated with impaired driving to a small extent (Frittelli et al., 2009) and self-reported road accident involvement is correlated with future diagnosis of dementia (Lafont et al., 2008). It is unknown whether distraction affects the driving ability of neurology patients to the same extent as healthy persons. Because of the ageing population, the need to investigate this question becomes critical. Objective: To present preliminary findings from a recently funded research programme, National Strategic Reference Framework (NSRF 2007-13, O.P. Thales), on the causes and impact of driver distraction in a driving simulator experiment. Patients and methods: At least 90 patients with neurological disorders (MCI, mild Alzheimer's disease, Parkinson's disease) will be recruited, and will be compared with at least 60 middle aged and older participants. A neuropsychological battery that measures attention, memory, visual and executive functions, a neurological exam, and a detailed history of medication and sleep difficulties are included. Results: Preliminary findings are presented on the impact of presence/severity of neurological disorder, use of medications, and sleep disorders on driving performance with and without distraction, under different driving conditions. Conclusion: The neurological parameters that predict driving performance under different conditions are summarized and discussed. Preliminary recommendations are presented on criteria for safe driving.
doi:10.1016/j.jns.2013.07.1247
Abstract — WCN 2013 No: 2313 Topic: 5 — Dementia Potential effect of amyloid imaging on diagnosis and intended management of patients with cognitive decline: Impact of appropriate use criterion M.J. Pontecorvoa, A. Siderowfa, G. Dell'Agnellob, M. Lua, C. Hunterc, A.K. Aroraa, M.A. Mintuna. aAvid Radiopharmaceuticals, Philadelphia, PA, USA; bEli Lilly and Company, Florence, Italy; cEli Lilly and Company, Indianapolis, IN, USA Background: Published appropriate use criteria (AUC) by Johnson et al. (2013), provide guidelines for selecting patients for whom amyloid PET could be useful. Objectives: To evaluate the impact of amyloid PET on diagnosis and intended management in a set of patients likely to meet AUC.